Skip to main content

Table 3 Dose response series for local control and late effects

From: Conventional fractionation should not be the standard of care for T2 glottic cancer

Series Total Dose (Gy) Dose per fraction (Gy) OTT (days) BED10a(Gy) 5-year LC (%) BED3 (Gy) Late effects (%)
Current series, 2017 52.5 3.28 22 69.7 82 110 1.8
Ermis, 2015 [10] 55 2.75 28 67.1 81 105 1.6
Motegi, 2015 [15] 64.8 2.4 37 68.4 77 117 4.5b
Berwouts, 2015 [16] 70 2 47 62.0 75 117 nr
Trotti, 2014 [17] 79.2 1.2 45 68.7 78 111 4.2
Trotti, 2014 [17] 70 2 47 62.0 70 117 2.5
Karasawa, 2013 [41] 63 2.25 41 61.2 69 110 0.0
Chera, 2010 [9] 65.3 2.25 39 65.9 76 114 1.2
Garden, 2003 [7] 70 2 47 62.0 72 117 2.6
Warde, 1998 [5] 50 2.5 28 59.5 69 92 nr
  1. aUsing L = 25, T = 1; bFor T2 subgroup; nr not reported